Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES
- Sponsors MaaT Pharma
- 21 Mar 2018 Dates are not mentioned in EudraCT please update once more information become available.
- 17 Mar 2018 Status changed from planning to recruiting.
- 13 Mar 2018 New trial record